home / stock / nlnk / nlnk quote
Last: | $ |
---|---|
Change Percent: | -2.47% |
Open: | $1.63 |
Close: | $1.58 |
High: | $1.65 |
Low: | $1.57 |
Volume: | 183,508 |
Last Trade Date Time: | 02/12/2020 04:48:19 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $1.63 | $1.58 | $1.65 | $1.57 | 183,508 | 02-12-2020 |
$ | $1.63 | $1.62 | $1.64 | $1.56 | 185,803 | 02-11-2020 |
$ | $1.65 | $1.61 | $1.67 | $1.57 | 298,310 | 02-10-2020 |
$ | $1.75 | $1.66 | $1.75 | $1.64 | 302,819 | 02-07-2020 |
$ | $1.74 | $1.75 | $1.7636 | $1.71 | 237,213 | 02-06-2020 |
$ | $1.76 | $1.75 | $1.78 | $1.68 | 305,280 | 02-05-2020 |
$ | $1.68 | $1.74 | $1.77 | $1.66 | 628,781 | 02-04-2020 |
$ | $1.69 | $1.66 | $1.78 | $1.62 | 350,412 | 02-03-2020 |
$ | $1.63 | $1.64 | $1.67 | $1.56 | 509,952 | 01-31-2020 |
$ | $1.65 | $1.63 | $1.6694 | $1.58 | 390,862 | 01-30-2020 |
$ | $1.73 | $1.65 | $1.75 | $1.63 | 425,883 | 01-29-2020 |
$ | $1.72 | $1.72 | $1.83 | $1.67 | 425,682 | 01-28-2020 |
$ | $1.74 | $1.71 | $1.82 | $1.71 | 459,260 | 01-27-2020 |
$ | $2.00 | $1.82 | $2.01 | $1.82 | 591,347 | 01-24-2020 |
$ | $2.03 | $2.00 | $2.03 | $1.94 | 333,206 | 01-23-2020 |
$ | $2.30 | $2.04 | $2.33 | $2.01 | 662,357 | 01-22-2020 |
$ | $2.04 | $2.26 | $2.40 | $2.04 | 1,210,301 | 01-21-2020 |
$ | $1.99 | $2.04 | $2.08 | $1.9301 | 682,356 | 01-20-2020 |
$ | $1.99 | $2.04 | $2.08 | $1.9301 | 681,501 | 01-17-2020 |
$ | $1.97 | $1.99 | $2.10 | $1.94 | 287,269 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash ...